Prior Axitinib as a Determinant of Outcome of Renal Surgery
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This is a single arm phase II study of axitinib in patients with clear cell renal cell
carcinoma (RCC) with strong indications for partial nephrectomy (PN) for whom PN is not
currently possible due to anatomic considerations and residual renal function concerns.
Evaluation of tumor downsizing will be performed including changes of tumor complexity by
nephrometry score. A total of 50 participants will be enrolled.
It is hypothesized that pretreatment with axitinib will be safe and improve the feasibility
of complex nephron sparing surgery in select patients with localized clear cell RCC and
imperative indications for partial nephrectomy.